Prospective, Randomized, Double-Blind Study, Comparing Botulinum Toxins Type A Botox and Prosigne for Blepharospasm and Hemifacial Spasm Treatment-Reference-Cited by-同舟云学术

Prospective, Randomized, Double-Blind Study, Comparing Botulinum Toxins Type A Botox and Prosigne for Blepharospasm and Hemifacial Spasm Treatment

Published:2010-01 Issue:1 Volume:33 Page:27-31
ISSN:0362-5664
Container-title:Clinical Neuropharmacology
language:en
Short-container-title:

Author:

Quagliato Elizabeth Maria Aparecida Barasnevicius,Carelli Edmur Franco,Viana Maura Aparecida

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Clinical Neurology,Pharmacology

Reference18 articles.

1. Epidemiology of primary blepharoespasm.;Defazio;Mov Disord,2002

2. Blepharospasm, oromandibular dystonia, Meige's syndrome and hemifacial spasm. In: Moore P, Naumann M, eds. Handbook of Botulinum Toxin Treatment. 2nd ed.;Brin;Blackwell Science,2003

3. Bells palsy: from viral aetiology to diagnostic reality in French.;Tankere;Rev Med Interne,2009

4. Botulinum A toxin injections as a treatment for blepharospasm.;Scott;Arch Ophthalmol,1985

5. Properties and use of botulinum toxin and other microbial neurotoxins in medicine.;Schantz;Microbiol Rev,1992

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes following a break in ophthalmic botulinum toxin therapy during the COVID-19 pandemic;Canadian Journal of Ophthalmology;2022-11

2. Adverse events after different forms of botulinum neurotoxin A injections in children with cerebral palsy: An 8‐year retrospective study;Developmental Medicine & Child Neurology;2022-06-08

3. Hengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial;Frontiers in Pharmacology;2022-02-18

4. Botulinum Neurotoxins as a Therapeutic;Handbook of Neurotoxicity;2022

5. Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies;Toxins;2021-12-09